# Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

> **NCT01446250** · PHASE3 · TERMINATED · sponsor: **Debiopharm International SA** · enrollment: 8 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Alisporivir
- **DRUG:** Boceprevir
- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01446250
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01446250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01446250, "Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01446250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*